Epidemiological characteristics of MTB/HIV co-infection in Yunnan Province from 2010 to 2020

doi:10.19983/j.issn.2096-8493.20220133

Abstract

Abstract:

Objective: To analyze the epidemic pattern of MTB/HIV co-infection in Yunnan Province, and to provide scientific basis for the prevention and control of MTB/HIV co-infection. Methods: The data of screening and diagnosis of MTB/HIV co-infection cases from 2010 to 2020 were obtained from the Tuberculosis management information system and MTB/HIV co-infection prevention and management annual report. Descriptive statistics and trend test were used to analyze the epidemiological characteristics of MTB/HIV co-infection over time. Results: From 2010 to 2020, the proportion of HIV/AIDS patients receiving TB testing increased from 25.01% to 91.26%, the detection positive rate decreased from 4.03% to 0.42%, and the proportion of TB patients receiving HIV antibody testing increased from 24.04% to 98.33%, the detection positive rate decreased from 0.72% to 0.30%. The ratio of male to female was about 4.2∶1 (4000∶960) among all tested positive MTB/HIV co-infection patients. The proportion of farmers, patients aged over 45 years old, patients without patient delay (the interval between onset of suspicious symptoms of tuberculosis and visit to medical institutions <14 days), and etiologically positive patients among all registered MTB/HIV co-infection patients increased from 49.50% (198/400), 18.00% (72/400), 30.75% (123/400), 16.75% (67/400) in 2010 to 84.13% (477/567), 40.04% (227/567), 37.63% (213/566), 47.62% (270/567) in 2020, which all showed an increasing trend year by year (Z_trend values were -14.617, 11.833, -5.628, -10.118 respectively, P<0.001). Conclusion: The implementation of MTB/HIV co-infection screening strategy in Yunnan Province has achieved remarkable results. However, it is still necessary to continue to improve the quality of all aspects of screening, take more effective prevention and control measures, and detect patients as much as possible, so as to control the epidemic of MTB/HIV co-infection to a greater extent.

Key words: Tuberculosis, pulmonary, HIV infections, Comorbidity, Disease attributes

CLC Number:

R512.91
R52

Yang Rui, Xu Lin, Li Ling. Epidemiological characteristics of MTB/HIV co-infection in Yunnan Province from 2010 to 2020[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(6): 437-442. doi: 10.19983/j.issn.2096-8493.20220133

Figures/Tables 4

类别	总例数	2010年		2011年		2012年		2013年		2014年		2015年		2016年		2017年		2018年		2019年		2020年
类别	总例数	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)
性别
男性	4000	319	79.75	328	79.61	344	80.00	294	80.11	284	80.91	273	82.23	300	81.52	361	79.34	485	81.65	565	82.60	447	78.84
女性	960	81	20.25	84	20.39	86	20.00	73	19.89	67	19.09	59	17.77	68	18.48	94	20.66	109	18.35	119	17.40	120	21.16
职业
农民	3788	198	49.50	247	59.95	311	72.33	273	74.39	281	80.06	267	80.42	301	81.79	384	84.40	483	81.31	566	82.75	477	84.13
非农民	1172	202	50.50	165	40.05	119	27.67	94	25.61	70	19.94	65	19.58	67	18.21	71	15.60	111	18.69	118	17.25	90	15.87
治疗分类
初治	4425	82	20.50	395	95.87	424	98.60	353	96.19	340	96.87	324	97.59	360	97.83	424	93.19	558	93.94	649	94.88	516	91.01
复治	535	318	79.50	17	4.13	6	1.40	14	3.81	11	3.13	8	2.41	8	2.17	31	6.81	36	6.06	35	5.12	51	8.99
年龄组(岁)
<15	27	5	1.25	4	0.97	3	0.70	1	0.27	0	0.00	1	0.30	0	0.00	4	0.88	3	0.50	5	0.73	1	0.18
15~29	658	84	21.00	81	19.66	84	19.54	57	15.53	53	15.10	49	14.76	42	11.42	48	10.55	49	8.25	66	9.65	45	7.94
30~44	2704	239	59.75	252	61.17	227	52.79	217	59.13	193	54.99	188	56.63	204	55.43	223	49.01	307	51.68	360	52.63	294	51.85
45~59	1206	54	13.50	57	13.83	79	18.37	71	19.35	76	21.65	76	22.89	97	26.36	133	29.23	190	31.99	197	28.80	176	31.04
≥60	365	18	4.50	18	4.37	37	8.60	21	5.72	29	8.26	18	5.42	25	6.79	47	10.33	45	7.58	56	8.19	51	8.99
地区
边境州(市)	3256	243	60.75	273	66.26	283	65.81	240	65.40	229	65.24	203	61.14	242	65.76	318	69.89	401	67.51	459	67.11	365	64.37
非边境州(市)	1704	157	39.25	139	33.74	147	34.19	127	34.60	122	34.76	129	38.86	126	34.24	137	30.11	193	32.49	225	32.89	202	35.63
出现症状至就诊时间(d)^a
<14	1380	123	30.75	111	26.94	93	21.68	76	20.71	75	21.43	68	20.48	89	24.25	119	26.21	175	29.46	238	35.05	213	37.63
≥14	3570	277	69.25	301	73.06	336	78.32	291	79.29	275	78.57	264	79.52	278	75.75	335	73.79	419	70.54	441	64.95	353	62.37
诊断分类
病原学阳性	1703	67	16.75	148	35.92	117	27.21	109	29.70	106	30.20	81	24.40	98	26.63	148	32.53	249	41.92	310	45.32	270	47.62
病原学阴性	3077	297	74.25	238	57.77	295	68.60	250	68.12	242	68.95	241	72.59	266	72.28	299	65.71	319	53.70	351	51.32	279	49.21
无病原学结果	22	14	3.50	1	0.24	2	0.47	0	0.00	0	0.00	1	0.30	0	0.00	2	0.44	0	0.00	0	0.00	2	0.35
单纯结核性胸膜炎	118	10	2.50	13	3.16	8	1.86	8	2.18	1	0.28	8	2.41	4	1.09	5	1.10	26	4.38	21	3.07	14	2.47
单纯肺外结核	40	12	3.00	12	2.91	8	1.86	0	0.00	2	0.57	1	0.30	0	0.00	1	0.22	0	0.00	2	0.29	2	0.35
合计	4960	400	100.00	412	100.00	430	100.00	367	100.00	351	100.00	332	100.00	368	100.00	455	100.00	594	100.00	684	100.00	567	100.00

References 16

[1]	Greenall M, Kunii O, Thomson K, et al. Reaching vulnerable populations: lessons from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Bull World Health Organ, 2017, 95(2):159-161. doi:10.2471/BLT.16.179192. doi: 10.2471/BLT.16.179192 URL
[2]	World Health Organization. WHO consolidated guidelines on tuberculosis: Systematic screening for tuberculosis disease. Module 2: Screening. Geneva: World Health Organization, 2020.
[3]	厉虹淼, 唐飞, 陈双双, 等. 艾滋病与结核病双重感染的研究进展. 中华疾病控制杂志, 2020, 24(12): 1459-1464. doi:10.16462/j.cnki.zhjbkz.2020.02.007. doi: 10.16462/j.cnki.zhjbkz.2020.02.007 URL
[4]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization.
[5]	李乐, 周子豪, 吴群红, 等. HIV感染者/AIDS患者中结核病检出率的meta分析. 职业与健康, 2019, 35 (24):3437-3441.
[6]	赖钰基. 艾滋病合并结核病病人发现策略的研究. 北京: 中国疾病预防控制中心, 2011.
[7]	Maimaiti R, Zhang Y, Pan K, et al. High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. BMC Infect Dis, 2017, 17(1): 15. doi:10.1186/s12879-016-2152-4. doi: 10.1186/s12879-016-2152-4 URL pmid: 28056848
[8]	杨蕊, 邱玉冰, 苏玮玮, 等. 云南省TB/HIV双重感染患者抗结核治疗死亡危险因素生存分析. 中华疾病控制杂志, 2016, 20(12):1212-1226. doi:10.16462/j.cnki.zhjbkz.2016.12.007. doi: 10.16462/j.cnki.zhjbkz.2016.12.007 URL
[9]	何佳晋, 袁璐, 吴超. 2010—2019年中国艾滋病流行时空分布特征. 中华疾病控制杂志, 2022, 26(5): 541-546. doi:10.16462/j.cnki.zhjbkz.2022.05.009. doi: 10.16462/j.cnki.zhjbkz.2022.05.009 URL
[10]	王芸, 侯景龙, 杨蕊, 等. 云南省2010—2013年结核菌/艾滋病病毒双重感染者流行特征. 公共卫生与预防医学, 2015, 26(3): 8-11.
[11]	Joint United Nations Program on HIV/AIDS. 90-90-90 an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS, 2020.
[12]	揣征然, 张云辉, 赵雅琳, 等. 全球及中国AIDS最新疫情概况. 传染病信息, 2020, 33(6):501-503. doi:10.3969/j.issn.1007-8134.2020.06.002. doi: 10.3969/j.issn.1007-8134.2020.06.002 URL
[13]	王新霞, 吴晓美, 童涌. 艾滋病患者结核杆菌感染与其免疫功能及HIV载量的关系. 中国现代医生, 2022, 60(6):8-11,50.
[14]	Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol, 2018, 16(2): 80-90. doi:10.1038/nrmicro.2017.128. doi: 10.1038/nrmicro.2017.128 URL
[15]	韦辉, 李博, 蓝光华. 中国老年人群艾滋病流行特征研究进展. 应用预防医学, 2021, 27(2): 189-193.
[16]	中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识. 新发传染病电子杂志, 2022, 7(1):73-87. doi:10.19871/j.cnki.xfcrbzz.2022.01.017. doi: 10.19871/j.cnki.xfcrbzz.2022.01.017 URL

年份	MTB/HIV 双重感染患者(例)	结核病患者中发现 HIV/AIDS患者		HIV/AIDS患者中发现结核病患者		抗病毒治疗		抗结核治疗
年份	MTB/HIV 双重感染患者(例)	例数	占比(%)	例数	占比(%)	例数	治疗率(%)	例数	治疗率(%)
2010	467	38	8.14	429	91.86	279	59.74	449	96.15
2011	397	89	22.42	308	77.58	169	42.57	396	99.75
2012	434	88	20.28	346	79.72	232	53.46	418	96.31
2013	371	80	21.56	291	78.44	213	57.41	356	95.96
2014	350	104	29.71	246	70.29	207	59.14	335	95.71
2015	323	86	26.63	237	73.37	226	69.97	317	98.14
2016	385	90	23.38	295	76.62	277	71.95	372	96.62
2017	452	95	21.02	357	78.98	359	79.42	426	94.25
2018	599	90	15.03	509	84.97	469	78.30	573	95.66
2019	617	102	16.53	515	83.47	506	82.01	610	98.87
2020	536	82	15.30	454	84.70	461	86.01	519	96.83
合计	4931	944	19.14	3987	80.86	3398	68.91	4771	96.76